CoChat

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Open access

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

Background For patients with advanced hepatocellular carcinoma, sorafenib is the only approved drug worldwide, and outcomes remain poor. We aimed to assess the safety and efficacy of nivolumab, a programmed cell death protein-1 (PD-1) immune checkpoint inhibitor, in patients with advanced hepatocellular carcinoma with or without chronic viral hepatitis. Methods We did a phase 1/2, open-label, non-comparative, dose escalation and expansion trial (CheckMate 040) of nivolumab in adults (≥18 years) with histologically confirmed advanced hepatocellular carcinoma with or without hepatitis C or B (HCV or HBV) infection. Previous sorafenib treatment was allowed. A dose-escalation phase was conducted at seven hospitals or academic centres in four countries or territories (USA, Spain, Hong Kong, and Singapore) and a dose-expansion phase was conducted at an additional 39 sites in 11 countries (Canada, UK, Germany, Italy, Japan, South Korea, Taiwan). At screening, eligible patients had Child-Pugh scores of 7 or less (Child-Pugh A or B7) for the dose-escalation phase and 6 or less (Child-Pugh A) for the dose-expansion phase, and an Eastern Cooperative Oncology Group performance status of 1 or less. Patients with HBV infection had to be receiving effective antiviral therapy (viral load Findings Between Nov 26, 2012, and Aug 8, 2016, 262 eligible patients were treated (48 patients in the dose-escalation phase and 214 in the dose-expansion phase). 202 (77%) of 262 patients have completed tre…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(17)31046-2

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Cited by

See all 4,280

Metadata

Authors
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., Meyer, T., Kang, Y.-K., Yeo, W., Chopra, A., Anderson, J., dela Cruz, C., Lang, L., Neely, J., Tang, H., Dastani, H. B., & Melero, I.
Affiliations
  • University of Southern California (US)
  • Clinica Universidad de Navarra (ES)
  • University of Hong Kong (HK)
  • Providence Portland Medical Center (US)
  • Kindai University (JP)
  • National Taiwan University Hospital (TW)
  • Seoul National University Hospital (KR)
  • National Cancer Centre Singapore (SG)
  • University Hospital Frankfurt (DE)
  • University of Michigan (US)
  • The Royal Free Hospital (GB)
  • Asan Medical Center (KR)
  • Chinese University of Hong Kong (HK)
  • Bristol-Myers Squibb (United States) (US)
  • Centro de Investigación Biomédica en Red de Cáncer (ES)
Corresponding author
El-Khoueiry, Anthony B
Venue
The Lancet
Publisher
Elsevier BV
Published
2017-06
Volume
389
Issue
10088
Pages
2492-2502
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2606367731
Cited by
4,280
References
31
Citations by year
2026: 163 · 2025: 301 · 2024: 465 · 2023: 513 · 2022: 578 · 2021: 709 · 2020: 641 · 2019: 487 · 2018: 330 · 2017: 88
FWCI
260.55
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
Funders
  • Japan Society for the Promotion of Science (15K09028)
  • National Cancer Institute (P30CA014089)
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
Keywords
nivolumab, hepatocellular carcinoma, immune checkpoint inhibitors, PD-1, hepatitis C, hepatitis B, sorafenib, dose escalation, objective response rate, safety and tolerability, antiviral therapy, advanced liver cancer, immunotherapy, Child-Pugh score, antitumor immunity, tumor-infiltrating lymphocytes
MeSH terms
Nivolumab, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Time Factors, Biomarkers, Tumor, Treatment Outcome, Tumor Burden, B7-H1 Antigen, Response Evaluation Criteria in Solid Tumors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. https://app.cochat.ai/papers/10.1016/s0140-6736(17)31046-2
The paper
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., Meyer, T., Kang, Y.-K., Yeo, W., Chopra, A., Anderson, J., dela Cruz, C., Lang, L., Neely, J., Tang, H., . . . Melero, I. (2017). Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. The Lancet. https://doi.org/10.1016/s0140-6736(17)31046-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.